API & Intermediate

Dihydroxycholecalciferol is vitamin 1 α， 25-d3 is one of the most important active metabolites. This metabolite is usually formed in the kidney. In recent years, it has been found that calcitriol can also be produced outside the kidney. It has been confirmed that there are 1 in placenta, monocytes, macrophages, tumor cell supernatant, lymph nodes and keratinocytes in patients with sarcoidosis α Hydroxylase can produce calcitriol. The precursor of calcitriol is 25 hydroxycholecalciferol (afacalcitol). Dihydroxycholecalciferol can promote the absorption of calcium in the small intestine and regulate the transport of inorganic salts in bone.

Sulbuthimide is a high fat soluble synthetic vitamin B1 analogue, which has the activity of vitamin B1, can increase the content of vitamin B1 in the blood, and can play a therapeutic role for all vitamin B1 deficiency. Sulbuthimide can be used to promote growth, help digestion, especially carbohydrate digestion, improve mental status, maintain normal activities of nerve tissue, muscle and heart, reduce airsickness and seasickness, relieve pain after dental surgery, and contribute to the treatment of herpes zoster.

P-Fluoronitrobenzene is a structural unit of aryl fluorination and a common intermediate for the synthesis of many industrially useful compounds. It can be used to prepare new soluble aromatic polyimides and to synthesize tropisetron.

Bendamostine hydrochloride was first developed by ozegowski and his colleagues in the microbial experimental Association in Jena, Germany in the early 1860s. The initial purpose was to connect an alkylated nitrogen mustard (a non effective alkylating agent) with a purine and an amino acid. Compared with nitrogen mustard phenylbutyrate, the main advantage of the newly synthesized compound is its water solubility. It was widely used, but until the end of the cold war, the drug has been carried out in Europe for many single drugs or other drugs for the treatment of various hematological malignancies or non Hodgkin's lymphoma, multiple myeloma, CLL and breast cancer. The clinical effect is very significant, significantly reducing the rate of recurrence and mortality, and has little side effects. Good security. So far, bendamostine hydrochloride single drug or combined treatment has been designated as the first-line or second-line treatment option for a variety of hematological malignancies by European and American clinical guidelines.